Anti Viral Drugs Companies
Anti-viral drugs are designed to treat viral infections by inhibiting the replication of viruses.
Anti-viral drugs are designed to treat viral infections by inhibiting the replication of viruses.
Pfizer's Paxlovid transition to commercial distribution: November 2023, Pfizer's oral COVID-19 treatment Paxlovid transitioned from government-managed distribution to traditional commercial channels. This move aims to improve patient access and availability beyond government supply.
Gilead Sciences receives FDA approval for Sunvepra for cytomegalovirus (CMV) infections: September 2023, Gilead Sciences received FDA approval for Sunvepra (ciluprevvir/ganciclovir) for the treatment of CMV infections in adult hematopoietic stem cell transplant recipients.
Roche secures positive Phase 3 trial results for Actemra/RoActemra combination in preventing CMV disease: October 2023, Roche announced positive results from a Phase 3 trial evaluating the combination of Actemra/RoActemra (tocilizumab) with standard-of-care anti-viral therapy for preventing CMV disease in adult kidney transplant recipients.
List of Anti-viral drugs Key Companies in the Market
Anti Viral Drugs Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)